These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38708001)

  • 1. Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis.
    Fernández Fernández Ó; Costa-Frossard L; Martínez Ginés ML; Montero Escribano P; Prieto González JM; Ramió-Torrentà L; Aladro Y; Alonso Torres A; Álvarez Rodríguez E; Labiano-Fontcuberta A; Landete Pascual L; Miralles Martínez A; Moral Torres E; Oliva-Nacarino P
    Front Neurol; 2024; 15():1371644. PubMed ID: 38708001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain.
    Goicochea Briceño H; Higueras Y; Ruiz Pérez I; García Domínguez JM; Cuello JP; Meldaña Rivera A; Martínez Ginés ML
    Front Neurol; 2024; 15():1360032. PubMed ID: 38469589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat
    Fernandez O; Costa-Frossard L; Martínez-Ginés ML; Montero P; Prieto-González JM; Ramió-Torrentà L
    Front Neurol; 2021; 12():722801. PubMed ID: 34646229
    [No Abstract]   [Full Text] [Related]  

  • 4. Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis.
    Bruno A; Dolcetti E; Centonze D
    Front Neurol; 2021; 12():802918. PubMed ID: 35197915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms.
    Fernández Ó; Costa-Frossard L; Martínez-Ginés M; Montero P; Prieto JM; Ramió L
    Front Neurol; 2020; 11():152. PubMed ID: 32256440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
    Patti F; Chisari CG; Fernández Ó; Sarroca J; Ferrer-Picón E; Hernández Vicente F; Vila Silván C
    Eur J Neurol; 2022 Sep; 29(9):2744-2753. PubMed ID: 35590453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
    Guger M; Hatschenberger R; Leutmezer F
    Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nabiximols oromucosal spray (Sativex
    Garde N; Heibel M
    Drugs Context; 2024; 13():. PubMed ID: 38384931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
    Haupts MR; Essner U; Mäurer M
    Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS).
    Matza LS; Stewart KD; Phillips G; Delio P; Naismith RT
    Mult Scler Relat Disord; 2019 Oct; 35():253-261. PubMed ID: 31437740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.
    Collongues N; Vermersch P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):21-5. PubMed ID: 23369056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
    Sartori A; Dinoto A; Stragapede L; Mazzon G; Morelli ME; Pasquin F; Bratina A; Bosco A; Manganotti P
    Neurol Sci; 2021 Dec; 42(12):5037-5043. PubMed ID: 33742336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
    Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.
    Torri Clerici V; Brambilla L; Politi PL; Viggiani F; Mercurio S; Tonietti S; Ronzoni M; Crisafulli SG; Antozzi C; Tramacere I; Redemagni C; Confalonieri P
    Mult Scler Relat Disord; 2023 Jun; 74():104711. PubMed ID: 37062198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Paul F; Silván CV
    Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
    Chan A; Silván CV
    Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
    Vicente-Valor MI; Garcia-Llopis P; Mejia Andujar L; Antonino de la Camara G; García del Busto N; Lopez Tinoco MJ; Quintana Vergara B; Peiro Vilaplana C; Dominguez Moran JA; Sánchez Alcaraz A
    J Clin Pharm Ther; 2013 Feb; 38(1):71-3. PubMed ID: 22726074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner.
    Oh J; Gagné-Brosseau MS; Guenette M; Larochelle C; Lemieux F; Menon S; Morrow SA; Poliquin-Lasnier L; Roy-Hewitson C; Rush C; Trudelle AM; Giacomini PS
    Can J Neurol Sci; 2018 May; 45(3):304-312. PubMed ID: 29756588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.
    Haddad F; Dokmak G; Karaman R
    Life (Basel); 2022 May; 12(5):. PubMed ID: 35629350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.